In a new, groundbreaking development in the fight against food allergies, the FDA has approved the first treatment for children with peanut allergies.
are unpredictable and severe reactions can occur from even the smallest trace of peanuts.
The Palforzia pill is administered in three phases and is taken over time, but cannot be used in an emergency situation in the way that a treatment like anThe first phase, called initial dose escalation, is consumed on a single day under the supervision of a medical professional, while up-dosing, the second phase, takes place over several months and involves 11 increased dose levels.
The drug itself is a powder made from peanuts that comes in color-coded capsules for the first two phases. In the maintenance phase, the drug comes in a sachet. The powder can be mixed with semi-soft foods such as applesauce and yogurt before a child consumes it. The FDA tested both the effectiveness and safety of the new drug in multiple double-blind, placebo-controlled studies with approximately 500 individuals with peanut allergies. Based on those studies, the potential side effects of Palforzia include abdominal pain, itching, tingling in the mouth, nausea, vomiting, cough, runny nose, throat irritation, tightness, hives, wheezing, shortness of breath and anaphylaxis.
While peanut allergy symptoms can vary among individuals, the most extreme response is anaphylaxis.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Jake Paul Destroys AnEsonGib In 1st Round KO, KSI Next?!Jake Paul was VIOLENT on Thursday -- mauling AnEsonGib in their big boxing match in Miami ... followed by an intense face-off with KSI.
Read more »
FDA Figures It Will Get Around To Regulating Supplements With Names Like Black Widow, Yellow DemonWASHINGTON—Saying that keeping an eye on the billion-dollar industry probably couldn’t hurt, the Food and Drug Administration reportedly figured aloud Thursday that sooner or later it would get around to regulating supplements with names like Black Widow and Yellow Demon. “I guess it wouldn’t be a bad idea at some point to assess the safety of products like energy pills that have a highly venomous spider on the logo and promise to ‘give your system a jolt’ once we get a few things off our plate,” said FDA official Donald Reece, adding that when they had the time, the agency’s chemists should really give a quick once-over to currently unregulated dietary products featuring the words “carnage,” “napalm,” “or “Hemo-Rage” written on the package in bold, fluorescent letters. “Now that I think about it, it probably makes sense to do at least a cursory study on any substance that consists of wholly untested chemical compounds and 6,000 times the recommended daily allotment of certain rare minerals. And if the container has the letter ‘X’ formed by two intersecting lightning bolts or a grimacing skull with glowing eyes, that might be a good reason to inspect it one of these days.” Reece, who confirmed that the FDA intends to look into these products eventually, said that a high-profile teenage athlete overdosing on a bodybuilding supplement named something like Doomsday Assault could get the ball rolling a lot faster.
Read more »
FDA Approves First Drug For Peanut AllergyTreatment from Aimmune Therapeutics provides a new option for the growing number of children and their families dealing with the life-threatening condition.
Read more »
FDA Issues Warning To Purell Over Claims It Can Prevent Ebola Or FluThe hand sanitizer company said it has begun updating information on its website in order to avoid legal action.
Read more »
The Latest: Kenin beats Muguruza in Australia for 1st majorMELBOURNE, Australia (AP) — The Latest on the Australian Open (all times local): 9:50 p.m. Sofia Kenin of the United States has beaten Garbiñe Muguruza of Spain to win the Australian...
Read more »
Abbott receives expanded FDA clearance for Parkinson's treatment - Business InsiderICYMI: The FDA's expanded clearance of Abbott's DBS system could help the medical giant broaden its portfolio of devices targeting neurological conditions
Read more »